![Julian Baker](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Julian Baker
Président chez
MADRIGAL PHARMACEUTICALS, INC.
Fortune : 37 M $ au 31/05/2026
Profil
Mr. Julian C.
Baker is a Chairman at Denali Therapeutics, Inc., an Independent Chairman at Madrigal Pharmaceuticals, Inc., an Independent Director at ACADIA Pharmaceuticals, Inc., a Chairman at Incyte Corp., a Managing Partner at Baker Bros.
Advisors LP, a Managing Member at Baker Bros.
Advisors GP LLC and a Partner at FBB Associates.
He is on the Board of Directors at ACADIA Pharmaceuticals, Inc. and EveryONE Medicines, Inc. Mr. Baker was previously employed as an Independent Director by Prelude Therapeutics, Inc., an Independent Director by Idera Pharmaceuticals, Inc., a Lead Independent Director by Genomic Health, Inc., a Portfolio Manager by Tisch Financial Management, a Member by CS FIRST BOSTON CORP, a Principal by CSFB Private Equity Partners LLC, and an Advisory Board Member by Elm Street Advisors LLC.
He also served on the board at Trimeris, Inc., Neurogen Corp., Theravance, Inc., Alumis, Inc. and Presidio Pharmaceuticals, Inc. He received his undergraduate degree from Harvard University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
INCYTE CORPORATION 0,14 % | 08/06/2026 | 278 773 ( 0,14 % ) | 27 M $ | 31/05/2026 |
BeiGene Ltd.
 BeiGene Ltd. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products 0,02 % | 22/05/2026 | 311 142 ( 0,02 % ) | 7 M $ | 31/05/2026 |
| 29/05/2026 | 102 876 ( 0,06 % ) | 2 M $ | 31/05/2026 | |
0,03 % | 29/05/2026 | 14 840 ( 0,03 % ) | 717 959 $ | 31/05/2026 |
DENALI THERAPEUTICS INC. 0,01 % | 31/03/2026 | 10 565 ( 0,01 % ) | 222 288 $ | 31/05/2026 |
Postes actifs de Julian Baker
| Sociétés | Poste | Début |
|---|---|---|
| INCYTE CORPORATION | Président | 26/06/2025 |
| ACADIA PHARMACEUTICALS INC. | Directeur/Membre du Conseil | 11/12/2015 |
| MADRIGAL PHARMACEUTICALS, INC. | Président | 15/06/2023 |
| DENALI THERAPEUTICS INC. | Président | 03/06/2025 |
Baker Bros. Advisors LP
 Baker Bros. Advisors LP Investment ManagersFinance BBA pursues a fundamentally driven approach to life sciences investing. The firm typically takes large, concentrated positions in the securities of life sciences companies with the potential for significant value creation over the long-term. They focus on public securities, but may, from time to time, recommend investments in private companies, life sciences and related healthcare intellectual property, royalty streams or other non-public investment opportunities. | Fondateur | 01/01/2000 |
EveryONE Medicines, Inc.
 EveryONE Medicines, Inc. Miscellaneous Commercial ServicesCommercial Services Develops precision therapeutics | Directeur/Membre du Conseil | - |
FBB Associates | Corporate Officer/Principal | - |
Baker Bros. Advisors GP LLC | Corporate Officer/Principal | - |
Anciens postes connus de Julian Baker
| Sociétés | Poste | Fin |
|---|---|---|
| PRELUDE THERAPEUTICS INCORPORATED | Directeur/Membre du Conseil | 12/06/2025 |
| ░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de Julian Baker
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
63
Relations au 1er degré
21
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 21 |
|---|---|
Incyte Corp.
 Incyte Corp. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of proprietary therapeutics | Health Technology |
Neurogen Corp.
 Neurogen Corp. Pharmaceuticals: MajorHealth Technology Discovers and develops drugs | Health Technology |
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Health Technology |
Trimeris, Inc.
 Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for viral diseases | Health Technology |
ACADIA Pharmaceuticals, Inc.
 ACADIA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals drugs for treatment of central nervous system disorders | Health Technology |
Baker Bros. Advisors LP
Baker Bros. Advisors LP Investment ManagersFinance BBA pursues a fundamentally driven approach to life sciences investing. The firm typically takes large, concentrated positions in the securities of life sciences companies with the potential for significant value creation over the long-term. They focus on public securities, but may, from time to time, recommend investments in private companies, life sciences and related healthcare intellectual property, royalty streams or other non-public investment opportunities. | Finance |
Genomic Health, Inc.
 Genomic Health, Inc. Medical/Nursing ServicesHealth Services Engages in genomic-based diagnostic tests for overtreatment and optimal treatment of early stage cancer | Health Services |
Baker Bros. Advisors GP LLC | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
FBB Associates | |
Credit Suisse First Boston Corp.
 Credit Suisse First Boston Corp. Real Estate Investment TrustsFinance Real Estate Investment Trusts | Finance |
Innoviva, Inc.
 Innoviva, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that manufactures respiratory drugs | Health Technology |
CSFB Private Equity Partners LLC
 CSFB Private Equity Partners LLC Investment ManagersFinance CSFB Private Equity invests in companies located in the United States and Europe. The firm focuses on companies operating in the fields of the market structure, financial technology, enterprise software, data analytics and specialty finance service sector. It provides financing for growth stage capital requirements. | Finance |
Presidio Pharmaceuticals, Inc.
 Presidio Pharmaceuticals, Inc. BiotechnologyHealth Technology Discovers and develops small-molecule antiviral therapeutics | Health Technology |
Elm Street Advisors LLC
 Elm Street Advisors LLC Investment ManagersFinance Elm Street Ventures invests in companies located in the United States. The firm targets companies operating across a broad range of sectors and industries. It provides financing for seed and early-stage capital requirements with an initial investment size of USD 0.5 - 2.5 million. It also makes follow-on investments. | Finance |
Denali Therapeutics, Inc.
 Denali Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops therapeutics for neurodegenerative diseases | Health Technology |
Prelude Therapeutics, Inc.
 Prelude Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops medicines targeting chromatin function to treat cancer and rare diseases | Health Technology |
Madrigal Pharmaceuticals, Inc.
 Madrigal Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops small-molecule drugs for cardiovascular, metabolic and liver diseases | Health Technology |
Tisch Financial Management | |
EveryONE Medicines, Inc.
EveryONE Medicines, Inc. Miscellaneous Commercial ServicesCommercial Services Develops precision therapeutics | Commercial Services |
Alumis, Inc.
 Alumis, Inc. Pharmaceuticals: MajorHealth Technology Engages in research and development of medicines for autoimmune disorders | Health Technology |
